Karyopharm Therapeutics Inc. buy tamam
Start price
06.11.19
/
50%
€13.00
Target price
04.11.21
€23.00
Performance (%)
-46.11%
End price
05.11.21
€7.01
Summary
This prediction ended on 05.11.21 with a price of €7.01. Massive losses of -46.11% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | -0.917% | -0.917% | -68.522% | -87.049% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by tamam for this prediction
In the thread Karyopharm Therapeutics Inc. diskutieren
Buy mit Kursziel 18,0
Karyopharm Therapeutics (KPTI) continues to be the apple of several analysts' eyes this week after an excellent third quarter. Wedbush is maintaining its Outperform rating on this small oncology concern but lifting its price target three bucks a share to $18. Wedbush's analyst states the following around his newfound enthusiasm for the stock.
A better-than-expected XPOVIO launch in penta-refractorymultiple myeloma that highlights the high unmet need for novel, differentiated therapies for the cancer. In both the U.S. and EU combined, the analyst now sees XPOVIO approaching $300M in net sales in penta-refractory MMalone, with an additional greater than$350M opportunity in earlier lines of therapy'
Kursziel geändert auf 23,0
In the thread Trading Karyopharm Therapeutics Inc.
Die von tamam gewählte maximale Laufzeit wurde überschritten